Mortality rate, disability at 3 to 6 months and at 1 year or more
. | . | Acute death, no. (%) . | Total death, no. (%) . | Outcome at 3 to 6 mo, no. patients . | . | . | Outcome at 1 y or more, no. patients . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study, year . | No. of patients . | . | . | Tot . | Death . | Level of disability . | Tot . | Death . | Level of disability . | ||||
| Appenzeller et al,28 2005 | 24 | 0 (0) | 0 (0) | NA | NA | NA | 24 | 0 | Complete recovery: 13; neurologic impairment: 11 | ||||
| Stolz et al,9,10 2005 | 79 | 12 (15.2) | 14 (17.7) | 62 | 0 | mRS 0-1: 54; mRS 2-3: 4; mRS 4-5: 4 | 58 | 2 | mRS 0-1: 50; mRS 2-3: 2; mRS 4-5: 4 | ||||
| Ferro et al,1,27 2005 | 624 | 27 (4.3) | 52 (8.3) | 589 | 15 | mRS 0-1: 481; mRS 2: 49; mRS 3-5: 44 | 582 | 10 | mRS 0-1: 493; mRS 2: 47; mRS 3-5: 32 | ||||
| Favrole et al,11 2004 | 28 | 0 (0) | 0 (0) | 28 | 0 | mRS 0-1: 26; mRS 2: 1; mRS 4: 1 | NA | NA | NA | ||||
| Baumgartner et al,12 2003 | 33 | 0 (0) | 0 (0) | NA | NA | NA | 33 | 0 | mRS 0-2: 27; mRS > 2: 6 | ||||
| Buccino et al,13 2003 | 36 | NA | 1 (2.8) | NA | NA | NA | 35 | 1 | mRS 0-1: 34 | ||||
| Cakmak et al,14 2003 | 16 | 0 (0) | 0 (0) | 16 | 0 | mRS 0-1: 9; mRS 2: 5; mRS 3-5: 2 | NA | NA | NA | ||||
| Breteau et al,21 2003 | 55 | 4 (7.3) | 7 (12.7) | NA | NA | NA | 51 | 3 | mRS 0-2: 45; mRS 3-5: 3 | ||||
| Ferro et al,16 2002 | 142 | 9 (6.3) | 11 (7.7) | NA | NA | NA | 126 | 2 | mRS 0-1: 108; mRS 2: 12; mRS 3-5: 4 | ||||
| Strupp et al,17 2002 | 40 | NA | NA | NA | NA | NA | 40 | NA | Complete or partial recovery: 29; focal neurologic deficits: 11 | ||||
| Fink and McAuley,18 2001 | 25 | NA | 1 (4) | NA | NA | NA | 25 | 1 | mRS 0-1: 16; mRS 2: 7; mRS > 3: 1 | ||||
| de Bruijn et al,4,19 2001 | 59 | 6 (10.2) | 8 (13.6) | 53 | 0 | mRS 0-2: 49; mRS > 3: 4 | 49 | 2 | mRS 0-1: 25; mRS 2-3: 19; mRS > 3: 3 | ||||
| Lleo et al,23 1999 | 17 | 0 (0) | 2 (11.8) | 17 | 2 | mRS 0-2: 10; mRS 3-5: 5 | NA | NA | NA | ||||
| Preter et al,24 1996 | 85 | 6 (7.1) | 8 (9.4) | 79 | 2 | NA | 77 | 0 | mRS 0-1: 66; optic atrophy: 2; seizure alone: 4; neuropsychiatric disturbance: 3; hemispheric deficit: 1; multiple cn palsies, cerebellar incoordination: 1 | ||||
| Rondepierre et al,25 1995 | 18 | 2 (11.1) | 7 (39) | 16 | 5 | GOS 1-2: 10; GOS 3-5: 1 | NA | NA | NA | ||||
| Bienfait et al,26 1995 | 62 | NA | 11 (17.7) | 62 | 11 | mRS 0-2: 41; mRS 3-5: 10 | NA | NA | NA | ||||
. | . | Acute death, no. (%) . | Total death, no. (%) . | Outcome at 3 to 6 mo, no. patients . | . | . | Outcome at 1 y or more, no. patients . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study, year . | No. of patients . | . | . | Tot . | Death . | Level of disability . | Tot . | Death . | Level of disability . | ||||
| Appenzeller et al,28 2005 | 24 | 0 (0) | 0 (0) | NA | NA | NA | 24 | 0 | Complete recovery: 13; neurologic impairment: 11 | ||||
| Stolz et al,9,10 2005 | 79 | 12 (15.2) | 14 (17.7) | 62 | 0 | mRS 0-1: 54; mRS 2-3: 4; mRS 4-5: 4 | 58 | 2 | mRS 0-1: 50; mRS 2-3: 2; mRS 4-5: 4 | ||||
| Ferro et al,1,27 2005 | 624 | 27 (4.3) | 52 (8.3) | 589 | 15 | mRS 0-1: 481; mRS 2: 49; mRS 3-5: 44 | 582 | 10 | mRS 0-1: 493; mRS 2: 47; mRS 3-5: 32 | ||||
| Favrole et al,11 2004 | 28 | 0 (0) | 0 (0) | 28 | 0 | mRS 0-1: 26; mRS 2: 1; mRS 4: 1 | NA | NA | NA | ||||
| Baumgartner et al,12 2003 | 33 | 0 (0) | 0 (0) | NA | NA | NA | 33 | 0 | mRS 0-2: 27; mRS > 2: 6 | ||||
| Buccino et al,13 2003 | 36 | NA | 1 (2.8) | NA | NA | NA | 35 | 1 | mRS 0-1: 34 | ||||
| Cakmak et al,14 2003 | 16 | 0 (0) | 0 (0) | 16 | 0 | mRS 0-1: 9; mRS 2: 5; mRS 3-5: 2 | NA | NA | NA | ||||
| Breteau et al,21 2003 | 55 | 4 (7.3) | 7 (12.7) | NA | NA | NA | 51 | 3 | mRS 0-2: 45; mRS 3-5: 3 | ||||
| Ferro et al,16 2002 | 142 | 9 (6.3) | 11 (7.7) | NA | NA | NA | 126 | 2 | mRS 0-1: 108; mRS 2: 12; mRS 3-5: 4 | ||||
| Strupp et al,17 2002 | 40 | NA | NA | NA | NA | NA | 40 | NA | Complete or partial recovery: 29; focal neurologic deficits: 11 | ||||
| Fink and McAuley,18 2001 | 25 | NA | 1 (4) | NA | NA | NA | 25 | 1 | mRS 0-1: 16; mRS 2: 7; mRS > 3: 1 | ||||
| de Bruijn et al,4,19 2001 | 59 | 6 (10.2) | 8 (13.6) | 53 | 0 | mRS 0-2: 49; mRS > 3: 4 | 49 | 2 | mRS 0-1: 25; mRS 2-3: 19; mRS > 3: 3 | ||||
| Lleo et al,23 1999 | 17 | 0 (0) | 2 (11.8) | 17 | 2 | mRS 0-2: 10; mRS 3-5: 5 | NA | NA | NA | ||||
| Preter et al,24 1996 | 85 | 6 (7.1) | 8 (9.4) | 79 | 2 | NA | 77 | 0 | mRS 0-1: 66; optic atrophy: 2; seizure alone: 4; neuropsychiatric disturbance: 3; hemispheric deficit: 1; multiple cn palsies, cerebellar incoordination: 1 | ||||
| Rondepierre et al,25 1995 | 18 | 2 (11.1) | 7 (39) | 16 | 5 | GOS 1-2: 10; GOS 3-5: 1 | NA | NA | NA | ||||
| Bienfait et al,26 1995 | 62 | NA | 11 (17.7) | 62 | 11 | mRS 0-2: 41; mRS 3-5: 10 | NA | NA | NA | ||||
mRS indicates modified Rankin Score; GOS, Glasgow Outcome Scale; NA, not assessed; Tot, total number of evaluable patients at each follow-up visit; Death, total number of patient deaths at each follow-up visit; and Level of disability, number of patients with different levels of disability.